These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 28426099)

  • 1. Improving brain penetration of kinase inhibitors in lung cancer patients with oncogene dependency.
    Remon J; Soria JC
    Ann Oncol; 2017 Feb; 28(2):196-198. PubMed ID: 28426099
    [No Abstract]   [Full Text] [Related]  

  • 2. Oncogene addicted non-small-cell lung cancer: current standard and hot topics.
    Vecchiarelli S; Bennati C
    Future Oncol; 2018 Jun; 14(13s):3-17. PubMed ID: 29989448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors.
    Wrona A; Dziadziuszko R; Jassem J
    Cancer Treat Rev; 2018 Dec; 71():59-67. PubMed ID: 30366200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-receptor tyrosine kinase inhibitors in lung cancer.
    Hahn O; Salgia R
    Anticancer Agents Med Chem; 2007 Nov; 7(6):633-42. PubMed ID: 18045058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on systemic therapy of advanced non-small-cell lung cancer.
    Cufer T; Knez L
    Expert Rev Anticancer Ther; 2014 Oct; 14(10):1189-203. PubMed ID: 25098682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired resistance in oncogene-addicted non-small-cell lung cancer.
    Sini C; Tuzi A; Rossi G; Russo A; Pezzuto A
    Future Oncol; 2018 Jun; 14(13s):29-40. PubMed ID: 29989451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE; Gandhi L; Costa DB
    Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of CNS disease in ALK-positive non-small cell lung cancer: Is whole brain radiotherapy still needed?
    Wrona A
    Cancer Radiother; 2019 Sep; 23(5):432-438. PubMed ID: 31331844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status.
    Patil T; Aisner DL; Noonan SA; Bunn PA; Purcell WT; Carr LL; Camidge DR; Doebele RC
    Lung Cancer; 2016 Jun; 96():27-32. PubMed ID: 27133746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequencing therapies in oncogene-driven non-small-cell lung cancer: how to get the best mileage?
    Sukrithan V; Snyder R; Cheng H; Halmos B
    Future Oncol; 2019 Sep; 15(25):2899-2904. PubMed ID: 31424276
    [No Abstract]   [Full Text] [Related]  

  • 11. A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer.
    McGranahan T; Nagpal S
    Curr Treat Options Oncol; 2017 Apr; 18(4):22. PubMed ID: 28391420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Penetrating the evidence of EGFR and ALK tyrosine kinase inhibitors for non-small cell lung cancer brain metastases.
    Thomas CM; Lee CS
    J Oncol Pharm Pract; 2019 Apr; 25(3):623-637. PubMed ID: 30176786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment challenges in patients with ALK-positive non-small cell lung cancer and brain metatases].
    Zhou JY; Chen Q; Zhou JY
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):755-759. PubMed ID: 30347546
    [No Abstract]   [Full Text] [Related]  

  • 14. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
    Roskoski R
    Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data.
    Ryall KA; Shin J; Yoo M; Hinz TK; Kim J; Kang J; Heasley LE; Tan AC
    Bioinformatics; 2015 Dec; 31(23):3799-806. PubMed ID: 26206305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.
    Morris TA; Khoo C; Solomon BJ
    Drugs; 2019 Aug; 79(12):1277-1286. PubMed ID: 31313100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
    Shaw AT; Solomon BJ
    N Engl J Med; 2015 Feb; 372(7):683-4. PubMed ID: 25671264
    [No Abstract]   [Full Text] [Related]  

  • 18. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
    Arnaoutakis K
    N Engl J Med; 2015 Feb; 372(7):683. PubMed ID: 25671265
    [No Abstract]   [Full Text] [Related]  

  • 19. Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.
    Campo M; Al-Halabi H; Khandekar M; Shaw AT; Sequist LV; Willers H
    Oncologist; 2016 Aug; 21(8):964-73. PubMed ID: 27354669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.